Compare NX & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NX | LXEO |
|---|---|---|
| Founded | 1927 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 797.0M | 731.3M |
| IPO Year | 2008 | 2023 |
| Metric | NX | LXEO |
|---|---|---|
| Price | $17.11 | $7.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $28.00 | $18.60 |
| AVG Volume (30 Days) | 493.5K | ★ 605.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | N/A | ★ 75.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,837,641,000.00 | $654,000.00 |
| Revenue This Year | $3.18 | N/A |
| Revenue Next Year | $2.27 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 43.81 | N/A |
| 52 Week Low | $11.04 | $1.45 |
| 52 Week High | $22.90 | $10.99 |
| Indicator | NX | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 27.59 | 55.35 |
| Support Level | $16.09 | $6.90 |
| Resistance Level | $19.88 | $7.72 |
| Average True Range (ATR) | 0.89 | 0.46 |
| MACD | -0.66 | 0.13 |
| Stochastic Oscillator | 7.41 | 71.90 |
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.